Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
"We are very excited to continue our collaboration with Aurigene. Their business model offers a one stop solution for structure guided drug design, lead optimization and preclinical work. The Debio 0617 project aims at developing inhibitors targeting a key oncology pathway, which plays essential roles in various solid tumors and haematological malignancies," said Rolland-Yves Mauvernay, President & Founder of Debiopharm Group.
"Partnering with Debiopharm, a highly focused and successful drug development company, is highly synergistic for Aurigene, a drug discovery biotech. Aurigene has been collaborating with Debiopharm on two other programs for three years now, and the current licensing agreement with Debiopharm serves to reiterate the high quality of science and competence at Aurigene. This further strengthens the relationship between the companies," added CSN Murthy, CEO of Aurigene.
About Debiopharm Group
Debiopharm Group is a global biopharmaceutical development specialist that in-licenses promising biologics and small molecule drug candidates. It develops its products for global registration and maximum commercial potential for out-licensing to pharmaceutical partners for sales and marketing.
Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.
Founded in 1979 and headquartered in
For more information on Debiopharm Group, please visit: http://www.debiopharm.com.
With proprietary Structural Biology and Fragment-based Drug Design technology platforms, and experienced scientific leadership, Aurigene is a fully integrated operation with expertise in Hit Generation to Drug Development Candidates for IND nomination.
Debiopharm S.A. Contacts Maurice Wagner Director Corporate Affairs & Communications Tel.: +41(0)21-321-01-11 Fax: +41(0)21-321-01-69 email@example.com Additional Media Contacts In London Maitland Brian Hudspith Tel: +44(0)20-7379-5151 firstname.lastname@example.org Jo-Anne Lutjens Communications Manager Tel.: +41(0)79-370-27-15 Fax: +41(0)21-321-01-69 email@example.com In New York Russo Partners, LLC Wendy Lau Tel: +1-212-845-4272 Fax: +1-212-845-4260 firstname.lastname@example.org Aurigene Contacts Sonita Chada Manager, Corporate Communications Tel: +91-80-2852-1314 Sonita_c@aurigene.com
SOURCE The Debiopharm Group